Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Glendale, California 91206


Purpose:

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered as single doses to healthy adult volunteers and healthy elderly subjects. The study will consist of 2 parts:(1) a single dose in healthy adult volunteers, at doses up to 800 mg or the maximum dose that can be tolerated, (2) a single dose of 50 mg in healthy elderly volunteers.


Study summary:

The study will consist of 2 parts: (1) a single dose in healthy adult volunteers, at doses up to 100 mg or the maximum dose that can be tolerated, (2) a single dose of 25 mg or lower in healthy elderly volunteers.


Criteria:

Inclusion: - Healthy males and females - Aged 30 to 55 years, inclusive (Cohorts 1 through 5); aged 65 to 85 years, inclusive (Cohort 6) - Body mass index (BMI) of 18 to 32kg/m^2 at Screening - Additional inclusion criteria for Cohort 6 (healthy elderly subjects) Exclusion - Females of child-bearing potential - Personal or family history of neurological abnormalities - Any clinical abnormality of the electrocardiogram (ECG)at Screening and check-in - A family history of cardiac abnormalities - Thyroid abnormalities


NCT ID:

NCT01294540


Primary Contact:

Principal Investigator
Mark Yen
Glendale Adventist Medical Center, Glendale, California


Backup Contact:

N/A


Location Contact:

Glendale, California 91206
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.